Plasma Cytokines Profile in Subjects with Alzheimer’s Disease: Interleukin 1 Alpha as a Candidate for Target Therapy
Abstract
Background: Alzheimer’s disease (AD) is the main cause of the neurodegenerative disorder, which is not detected unless the cognitive deficits are manifested. An early prediagnostic specific biomarker preferably detectable in plasma and hence non-invasive is highly sought-after. Various hypotheses refer to AD, with amyloid-beta (Aβ) being the most studied hypothesis and inflammation being the most recent theory wherein pro-and anti-inflammatory cytokines are the main culprits. Materials and Methods: In this study, the cognitive performance of AD patients (n=39) was assessed using mini-mental state examination (MMSE), AD assessment scale-cognitive subscale (ADAS-cog), and clinical dementia rating (CDR). Their neuropsychiatric symptoms were evaluated through neuropsychiatric inventory–questionnaire (NPI-Q). Moreover, plasma levels of routine biochemical markers, pro-/anti-inflammatory cytokines such as tumor necrosis factor α (TNF-α), interleukin-1 α (IL-1α), IL-1β, IL-2, IL-4, IL-6, IL-8, IL-12p70, IL-10, Interferon-gamma, chemokines, including prostaglandin E2 (PGE-2), monocyte chemoattractant protein-1, interferon gamma-induced protein 10, Aβ peptide species (42, 40) and Transthyretin (TTR) were measured. Results: Our results revealed that Aβ 42/40 ratio and TTR were correlated (r=0.367, P=0.037). IL-1α was directly correlated with ADAS-cog (r=0.386, P=0.017) and Aβ 40 (r=0.379, P=0.019), but was inversely correlated with IL-4 (r=-0.406, P=0.011). Negative correlations were found between MMSE and PGE2 (r=-0.405, P=0.012) and TNF-α/ IL-10 ratio (r=-0.35, P=0.037). CDR was positively correlated with both PGE2 (r=0.358, P=0.027) and TNF-α (r=0.416, P=0.013). There was a positive correlation between NPI-caregiver distress with CDR (r=0.363, P=0.045) and ADAS-cog (r=0.449, P=0.019). Conclusion: Based on the observed correlation between IL-1α, as a clinical moiety, and ADAS-cog, as a clinical manifestation of AD, anti-IL-1α therapy in AD could be suggested. [GMJ.2021;10:e1974]References
Reitz C, R Mayeux. Alzheimer disease: epidemiology, diagnostic criteria, risk factors and biomarkers. Biochem Pharmacol. 2014; 88(4): 640-51.
https://doi.org/10.1016/j.bcp.2013.12.024
PMid:24398425 PMCid:PMC3992261
Dourlen P. The new genetic landscape of Alzheimer's disease: from amyloid cascade to genetically driven synaptic failure hypothesis? Acta Neuropathol. 2019; 138(2): 221-36.
https://doi.org/10.1007/s00401-019-02004-0
PMid:30982098 PMCid:PMC6660578
Volpato D, U Holzgrabe. Designing Hybrids Targeting the Cholinergic System by Modulating the Muscarinic and Nicotinic Receptors: A Concept to Treat Alzheimer's Disease. Molecules. 2018; 23(12): 3230.
https://doi.org/10.3390/molecules23123230
PMid:30544533 PMCid:PMC6320942
Evin G, A Weidemann. Biogenesis and metabolism of Alzheimer's disease Abeta amyloid peptides. Peptides. 2002; 23(7): 1285-97.
https://doi.org/10.1016/S0196-9781(02)00063-3
Yoon S S, S A Jo. Mechanisms of Amyloid-beta Peptide Clearance: Potential Therapeutic Targets for Alzheimer's Disease. Biomol Ther (Seoul). 2012; 20(3): 245-55.
https://doi.org/10.4062/biomolther.2012.20.3.245
PMid:24130920 PMCid:PMC3794520
Wyss-Coray T. Inflammation in Alzheimer disease: driving force, bystander or beneficial response? Nat Med. 2006; 12(9): 1005-15.
Heneka M T. Neuroinflammation in Alzheimer's disease. The Lancet Neurology. 2015; 14(4): 388-405.
https://doi.org/10.1016/S1474-4422(15)70016-5
Gonçalves N P, P Vieira, M J Saraiva. Interleukin-1 signaling pathway as a therapeutic target in transthyretin amyloidosis. Amyloid. 2014; 21(3): 175-84.
https://doi.org/10.3109/13506129.2014.927759
PMid:24918964 PMCid:PMC4196507
Swardfager W. A meta-analysis of cytokines in Alzheimer's disease. Biol Psychiatry. 2010; 68(10): 930-41.
https://doi.org/10.1016/j.biopsych.2010.06.012
PMid:20692646
Hickman S E, E K Allison, J El Khoury. Microglial dysfunction and defective beta-amyloid clearance pathways in aging Alzheimer's disease mice. J Neurosci. 2008; 28(33): 8354-60.
https://doi.org/10.1523/JNEUROSCI.0616-08.2008
PMid:18701698 PMCid:PMC2597474
Belkhelfa M. IFN-gamma and TNF-alpha are involved during Alzheimer disease progression and correlate with nitric oxide production: a study in Algerian patients. J Interferon Cytokine Res. 2014; 34(11): 839-47.
https://doi.org/10.1089/jir.2013.0085
PMid:24831467
Shaftel S S, W S Griffin, M K O'Banion. The role of interleukin-1 in neuroinflammation and Alzheimer disease: an evolving perspective. J Neuroinflammation. 2008; 5: 7.
https://doi.org/10.1186/1742-2094-5-7
PMid:18302763 PMCid:PMC2335091
Dursun E. The interleukin 1 alpha, interleukin 1 beta, interleukin 6 and alpha-2-macroglobulin serum levels in patients with early or late onset Alzheimer's disease, mild cognitive impairment or Parkinson's disease. J Neuroimmunol. 2015; 283: 50-7.
https://doi.org/10.1016/j.jneuroim.2015.04.014
PMid:26004156
Italiani P. Circulating levels of IL-1 family cytokines and receptors in Alzheimer's disease: new markers of disease progression? J Neuroimmunol. 2018; 15(1): 1-12.
https://doi.org/10.1186/s12974-018-1376-1
PMid:30541566 PMCid:PMC6292179
Lee S C. Cytokine production by human fetal microglia and astrocytes. Differential induction by lipopolysaccharide and IL-1 beta. J Immunol. 1993; 150(7): 2659-67.
Cojocaru I M. Study of interleukin-6 production in Alzheimer's disease. Rom J Intern Med. 2011; 49(1): 55-8.
Heneka M T. Neuroinflammation in Alzheimer's disease. Lancet Neurol. 2015; 14(4): 388-405.
https://doi.org/10.1016/S1474-4422(15)70016-5
Leung R. Inflammatory proteins in plasma are associated with severity of Alzheimer's disease. PLoS One. 2013; 8(6): e64971.
https://doi.org/10.1371/journal.pone.0064971
PMid:23762274 PMCid:PMC3677891
D'Anna L. Serum Interleukin-10 Levels Correlate with Cerebrospinal Fluid Amyloid Beta Deposition in Alzheimer Disease Patients. Neurodegener Dis. 2017; 17(4-5): 227-34.
https://doi.org/10.1159/000474940
PMid:28719891
Johansson J U. Inflammatory Cyclooxygenase Activity and PGE2 Signaling in Models of Alzheimer's Disease. Curr Immunol Rev. 2015; 11(2): 125-31.
https://doi.org/10.2174/1573395511666150707181414
PMid:28413375 PMCid:PMC5384338
Hayney M S. Serum IFN-gamma-induced protein 10 (IP-10) as a biomarker for severity of acute respiratory infection in healthy adults. J Clin Virol. 2017; 90: 32-7.
https://doi.org/10.1016/j.jcv.2017.03.003
PMid:28334685 PMCid:PMC5408957
Sun Y X. Inflammatory markers in matched plasma and cerebrospinal fluid from patients with Alzheimer's disease. Dement Geriatr Cogn Disord. 2003; 16(3): 136-44.
https://doi.org/10.1159/000071001
PMid:12826739
Galimberti D.Serum MCP-1 levels are increased in mild cognitive impairment and mild Alzheimer's disease. Neurobiol Aging. 2006; 27(12): 1763-8.
https://doi.org/10.1016/j.neurobiolaging.2005.10.007
PMid:16307829
Lee W J. Plasma MCP-1 and Cognitive Decline in Patients with Alzheimer's Disease and Mild Cognitive Impairment: A Two-year Follow-up Study. Sci Rep. 2018; 8(1): 1280.
https://doi.org/10.1038/s41598-018-19807-y
PMid:29352259 PMCid:PMC5775300
Zheng C. X W Zhou. J Z Wang. The dual roles of cytokines in Alzheimer's disease: update on interleukins, TNF-alpha, TGF-beta and IFN-gamma. Transl Neurodegener. 2016; 5: 7.
https://doi.org/10.1186/s40035-016-0054-4
PMid:27054030 PMCid:PMC4822284
Wang W Y. Role of pro-inflammatory cytokines released from microglia in Alzheimer's disease. Ann Transl Med. 2015; 3(10): 136.
Guzman-Martinez L. Neuroinflammation as a Common Feature of Neurodegenerative Disorders. Front Pharmacol. 2019; 10: 1008.
https://doi.org/10.3389/fphar.2019.01008
PMid:31572186 PMCid:PMC6751310
Bu X L. Blood-derived amyloid-beta protein induces Alzheimer's disease pathologies. Mol Psychiatry. 2018; 23(9): 1948-56.
https://doi.org/10.1038/mp.2017.204
PMid:29086767
van Oijen. Plasma Abeta(1-40) and Abeta(1-42) and the risk of dementia: a prospective case-cohort study. Lancet Neurol. 2006; 5(8): 655-60.
https://doi.org/10.1016/S1474-4422(06)70501-4
Graff-Radford N R. Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease. Arch Neurol. 2007; 64(3): 354-62.
https://doi.org/10.1001/archneur.64.3.354
PMid:17353377
Fandos N, et al. Plasma amyloid beta 42/40 ratios as biomarkers for amyloid beta cerebral deposition in cognitively normal individuals.Amst. 2017; 8: 179-87.
https://doi.org/10.1016/j.dadm.2017.07.004
PMid:28948206 PMCid:PMC5602863
Gloeckner S F, et al. Quantitative analysis of transthyretin, tau and amyloid-beta in patients with dementia. J Alzheimers Dis. 2008; 14(1): 17-25.
https://doi.org/10.3233/JAD-2008-14102
PMid:18525124
Hansson S F, et al. Reduced levels of amyloid-beta-binding proteins in cerebrospinal fluid from Alzheimer's disease patients. J Alzheimers Dis. 2009; 16(2): 389-97.
https://doi.org/10.3233/JAD-2009-0966
PMid:19221428
Velayudhan L, et al. Plasma transthyretin as a candidate marker for Alzheimer's disease. J Alzheimers Dis. 2012; 28(2): 369-75.
https://doi.org/10.3233/JAD-2011-110611
PMid:22002789
Fedosov S N. Biochemical markers of vitamin B12 deficiency combined in one diagnostic parameter: the age-dependence and association with cognitive function and blood hemoglobin. Clin Chim Acta. 2013; 422: 47-53.
https://doi.org/10.1016/j.cca.2013.04.002
PMid:23583557
Siuda J, et al. From mild cognitive impairment to Alzheimer's disease - influence of homocysteine, vitamin B12 and folate on cognition over time: results from one-year follow-up. Neurol Neurochir Pol. 2009; 43(4): 321-9.
Smith, A D, H Refsum. Homocysteine, B Vitamins, and Cognitive Impairment. Annu Rev Nutr. 2016; 36: 211-39.
https://doi.org/10.1146/annurev-nutr-071715-050947
PMid:27431367
Blennow K, et al. Amyloid biomarkers in Alzheimer's disease. Trends Pharmacol Sci. 2015; 36(5): 297-309.
https://doi.org/10.1016/j.tips.2015.03.002
PMid:25840462
Agyare E K, et al. Engineering theranostic nanovehicles capable of targeting cerebrovascular amyloid deposits. J Control Release. 2014; 185: 121-9.
https://doi.org/10.1016/j.jconrel.2014.04.010
PMid:24735640
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution 4.0 International License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
